Just Published in Psychiatry Research: Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.
Transforming neuroscience-based innovation into accessible mental health therapy to help change lives.
GrayMatters Health is leading a transformation by empowering mental healthcare professionals with a neuroscience-based technology that augments standard-of-care therapies to improve patient outcomes and patient lives. This is all based on the world’s first digital biomarker of brain activity associated with mental health disorders.
Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct treatment for post-traumatic stress disorder (PTSD). The procedure is a new concept – digitizing brain activity associated with PTSD, giving patients an active role in learning to control brain biomarker activity and improve their symptoms.
IT IS SCIENCE-BASED.
Prism’s amygdala-based biomarker technology
has been extensively researched.
IT FITS YOUR CLINIC
Installation and training in the morning and treat patients that same afternoon. Can be operated by a non-MD.
In the clinical trial, 67% of patients overall showed clinically significant symptom improvement and 32% were in remission three months after treatment.
PTSD IS PERSONAL
By gamifying brain activity associated with PTSD, patients take an active role in improving their symptoms.
IT IS SAFE.
Only mild side effects were reported which self-resolved post treatment.
PATIENTS LIKE IT.
Prism does not expose patients to trauma and studies have shown
IMPACT ON PATIENTS
" I feel that I automatically respond better."